Literature DB >> 15319252

Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

G Cavaletti1, G Bogliun, L Marzorati, A Zincone, M Piatti, N Colombo, D Franchi, M T La Presa, A Lissoni, A Buda, F Fei, S Cundari, C Zanna.   

Abstract

BACKGROUND: We investigated the possible use of clinical signs of chemotherapy-induced peripheral neurotoxicity (CIPN) or of nerve growth factor (NGF) circulating levels to predict the final outcome of CIPN. PATIENTS AND METHODS: Sixty-two women affected by locally advanced squamous cervical carcinoma treated with TP (paclitaxel 175 mg/m2 over a 3 h infusion plus cisplatin 75 mg/m2) or TIP (TP plus ifosphamide 5 mg/m2) were examined and scored according to the Total Neuropathy Score (TNS), before and during chemotherapy.
RESULTS: A correlation with the final severity of CIPN was observed with vibration perception and deep tendon reflex evaluation, while pin sensibility, strength, and autonomic symptoms and signs were not informative. A highly significant correlation existed between the decrease in circulating levels of NGF and the severity of CIPN (r = -0.579; P < 0.001; 95% confidence limits -0.702 to -0.423). However, circulating levels of NGF were not effective as predictors of the final neurological outcome of each patient.
CONCLUSION: Our study indicates that a precise clinical evaluation of the peripheral nervous system of patients treated with platinum and taxane combination polychemotherapy not only gives reliable information regarding the course of CIPN, but also can be used to predict the final neurological outcome of the treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319252     DOI: 10.1093/annonc/mdh348

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  28 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 2.  Health-related quality of life in ovarian cancer patients and its impact on clinical management.

Authors:  Dana M Chase; Lari Wenzel
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-08       Impact factor: 2.217

3.  Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?

Authors:  Andreas A Argyriou; Panagiotis Polychronopoulos; Angelos Koutras; Gregoris Iconomou; Alexander Iconomou; Haralabos P Kalofonos; Elisabeth Chroni
Journal:  Support Care Cancer       Date:  2005-02-15       Impact factor: 3.603

4.  Pain in cancer survivors.

Authors:  Matthew Rd Brown; Juan D Ramirez; Paul Farquhar-Smith
Journal:  Br J Pain       Date:  2014-11

5.  Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.

Authors:  Rhonda J Moore; Hunter Groninger
Journal:  Cureus       Date:  2013-06-14

6.  Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer.

Authors:  Óscar Arrieta; N Hernández-Pedro; M C Fernández-González-Aragón; D Saavedra-Pérez; A D Campos-Parra; M Á Ríos-Trejo; T Cerón-Lizárraga; L Martínez-Barrera; B Pineda; G Ordóñez; A Ortiz-Plata; V Granados-Soto; J Sotelo
Journal:  Neurology       Date:  2011-08-24       Impact factor: 9.910

7.  Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy.

Authors:  Elisabeth G Vichaya; Xin Shelley Wang; Jessica A Boyette-Davis; Tito R Mendoza; Zijing He; Sheeba K Thomas; Nina Shah; Loretta A Williams; Charles S Cleeland; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-31       Impact factor: 3.333

8.  Chemotherapy-induced neuropathy.

Authors:  Guido Cavaletti; Paola Alberti; Barbara Frigeni; Marialuisa Piatti; Emanuela Susani
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

Review 9.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

10.  Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.

Authors:  Kathleen A Griffith; Susan G Dorsey; Cynthia L Renn; Shijun Zhu; Mary E Johantgen; David R Cornblath; Andreas A Argyriou; Guido Cavaletti; Ingemar S J Merkies; Paola Alberti; Tjeerd J Postma; Emanuela Rossi; Barbara Frigeni; Jordi Bruna; Roser Velasco; Haralabos P Kalofonos; Dimitri Psimaras; Damien Ricard; Andrea Pace; Edvina Galie; Chiara Briani; Chiara Dalla Torre; Catharina G Faber; Roy I Lalisang; Willem Boogerd; Dieta Brandsma; Susanne Koeppen; Joerg Hense; Dawn J Storey; Simon Kerrigan; Angelo Schenone; Sabrina Fabbri; Maria Grazia Valsecchi
Journal:  J Peripher Nerv Syst       Date:  2014-06       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.